0000000000248973

AUTHOR

A. Berruti

showing 3 related works from this author

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participat…

2020

Purpose Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article reports on the evolution of surgical management strategies for PCa in Italy. Methods The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences in patients' characteristics were evaluated. Multivariable logistic regression models were used to identify characteristics associated with robot-assisted (RA) procedure, nerve sparing (NS) approach, and lymph node dissection (LND). Results The two cohorts did not …

MaleNephrologymedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatment030232 urology & nephrologyLymph node dissectionLogistic regression03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineLUNA studyBiopsyHumansMedicineProspective StudiesNerve sparingLymph nodeAgedProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomyMIRROR SIU/LUNA studyLymph node dissection MIRROR SIU/LUNA study Nerve sparing Pros-IT CNR study Prostate cancer Robotic proceduresProstatic NeoplasmsCancerPros-IT CNR studyMiddle Agedmedicine.diseaseMIRROR SIUDissectionRobotic proceduresLogistic Modelsmedicine.anatomical_structureItaly030220 oncology & carcinogenesisLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic procedures; Aged; Humans; Italy; Logistic Models; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time FactorsLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic proceduresbusiness
researchProduct

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

2015

Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a medi…

MaleLung NeoplasmsENSATGastroenterologyPROPOSALClinical endpointAdrenocortical carcinomaENDOCRINEStage (cooking)Liver NeoplasmsIntraventricular blockHematologyMiddle AgedSERIESCANCEREuropeSurvival RateOncologymedicine.veinLymphatic MetastasisSURVIVALFemalemedicine.medical_specialtyUNITED-STATESBone NeoplasmsInferior vena cavaInternal medicineGRASmedicineadrenocortical carcinomaPrognostic factors adrenocortical carcinomaHumansNeoplasm InvasivenessSurvival rateAdrenocortical carcinoma; ENSAT; GRAS; Prognostic factors; Oncology; HematologyNeoplasm StagingRetrospective Studiesbusiness.industryCancerprognostic factorsRetrospective cohort studymedicine.diseaseAdrenal Cortex NeoplasmsSurgeryAdrenocortical carcinoma prognosisprognosisNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct